INOVIO PHARMACEUTICALS, INC.
Ownership & governance
Executives 5Directors 8Avg age 66Avg tenure 8.7y
JS
Jacqueline Shea
Chief Executive Officer
Age 60Since 2022-05-09Profile →
+12
Executives5
JS
Jacqueline Shea→
Chief Executive Officer
Age 60Since 2022-05-09
PK
Peter Kies→
Director of Finance/CFO
Age 62Since 2002-05-31
MS
Michael Sumner→
Chief Tech/Sci/R&D Officer
Age 60Since 2022-06-26
RC
Robert L. Crotty→
Compliance Officer
Age 52Since 2021-11-04
SK
Stephen Kemmerrer→
Chief Tech/Sci/R&D Officer
—Since 2007-01-31
Board of directors8
SB
Simon Benito→
Chairman
Age 81Since 2019-01-02
DW
David Weiner→
Director/Board Member
Age 69Since 2016-03-10
WY
Wendy Yarno→
Director/Board Member
Age 71Since 2017-12-05
LZ
Lota Zoth→
Director/Board Member
Age 66Since 2017-12-31
JS
Jacqueline Shea→
Director/Board Member
Age 60Since 2022-05-15
AM
Ann Miller→
Director/Board Member
Age 68Since 2019-03-24
JS
Jay Shepard→
Director/Board Member
Age 68Since 2020-01-14
RD
Roger Dansey→
Director/Board Member
Age 69Since 2021-05-12
Shareholders5
| Name | Stake | Shares |
|---|---|---|
| Fidelity Management & Research Co. LLC | 11.35 % | 9,339,614 |
| Janus Henderson Investors US LLC | 4.021 % | 3,308,406 |
| Vanguard Capital Management LLC | 3.526 % | 2,901,208 |
| Boxer Capital Management LLC | 2.881 % | 2,370,122 |
| D.E. Shaw & Co., Inc. | 2.69 % | 2,212,819 |
Catalog · 2026-07-09
Registry officers13
| Name | Role | Since | Shares |
|---|---|---|---|
| Jacqueline Shea | Chief Executive Officer | 2022-05-09 | - |
| Michael Sumner | Chief Tech/Sci/R&D Officer | 2022-06-26 | - |
| Peter Kies | Director of Finance/CFO | 2002-05-31 | - |
| Simon Benito | Chairman | 2019-01-02 | - |
| Stephen Kemmerrer | Chief Tech/Sci/R&D Officer | 2007-01-31 | - |
| Ann Miller | Director/Board Member | 2019-03-24 | - |
| David Weiner | Director/Board Member | 2016-03-10 | - |
| Jacqueline Shea | Director/Board Member | 2022-05-15 | - |
Registry · as of 2026-07-09
Institutional (13F)
Loading Form 13F holders…
Fund membership
Loading fund baskets…
Street consensus
Consensus noneMean target 3.17Range 2.5–4Analysts 3
2.5Mean 3.174
- Strong buy 1
- Buy 1
- Hold 1
Broker actions22
| Firm | Action | To | Target | Date |
|---|---|---|---|---|
| Jefferies | Upgrade | Buy | 3 | 2026-08-13 |
| Piper Sandler | Reiterated | Overweight | 4 | 2026-08-03 |
| HC Wainwright & Co. | Maintained | Neutral | 2.5 | 2026-06-01 |
| Piper Sandler | Reiterated | Overweight | 6 | 2025-11-14 |
| HC Wainwright & Co. | Reiterated | Neutral | 3 | 2025-08-14 |
| Piper Sandler | Initiated | Overweight | 5 | 2025-07-09 |
| RBC Capital | Reiterated | Sector Perform | 5 | 2025-05-14 |
| Oppenheimer | Maintained | Outperform | 13 | 2025-05-14 |
| RBC Capital | Maintained | Sector Perform | 5 | 2025-03-19 |
| HC Wainwright & Co. | Reiterated | Neutral | 3 | 2025-03-19 |
| HC Wainwright & Co. | Maintained | Neutral | 3 | 2025-01-13 |
| JMP Securities | Reiterated | Market Outperform | 18 | 2025-01-10 |
Firm rows and rating mix from Yahoo Finance; mean target is Yahoo’s aggregate until OpenFilings derives consensus from broker rows.